Overview

• The phase 3 INAVO120 trial enrolled 325 patients across 28 countries using liquid biopsy screening to identify PIK3CA-mutated HR+ HER2- breast cancer.
• The inavolisib, palbociclib and fulvestrant combination extended median overall survival by seven months, from 27 to 34 months, versus palbociclib and fulvestrant alone.
• The triple regimen delayed median disease progression by 17.2 months compared with 7.3 months in the control arm, allowing patients to postpone chemotherapy by nearly two years.
• The therapy was generally well tolerated, with few patients discontinuing treatment due to adverse effects.
• Results published in the New England Journal of Medicine and presented at ASCO support MHRA and NICE review ahead of potential UK approval.